▁Anal 8.7265625
yst 1.58984375
s 0.73876953125
▁and 3.89453125
▁medical 8.3203125
▁exper 0.7236328125
ts 4.279613494873047e-05
▁eager 10.1171875
ly 0.224365234375
▁await 0.211181640625
▁the 1.3134765625
▁up 5.11328125
coming 0.0043182373046875
▁European 6.28125
▁Society 2.66015625
▁for 1.451171875
▁Medical 0.1297607421875
▁On 0.0045166015625
col 0.0010833740234375
ogy 8.26120376586914e-05
' 4.765625
s 0.01119232177734375
▁( 0.69921875
ES 0.0121307373046875
MO 0.0001385211944580078
) 0.0357666015625
▁annual 1.486328125
▁meeting 0.80712890625
, 1.193359375
▁set 3.482421875
▁to 0.2203369140625
▁take 0.623046875
▁place 0.004146575927734375
▁later 4.66796875
▁this 0.04241943359375
▁month 0.2017822265625
, 2.091796875
▁where 2.171875
▁new 3.013671875
▁evidence 5.515625
▁regarding 2.7109375
▁British 13.1796875
▁Bi 3.478515625
ote 0.0041656494140625
ch 0.0201416015625
' 1.6669921875
s 0.0007810592651367188
▁highly 7.953125
▁anticip 0.556640625
ated 0.0009889602661132812
▁anti 4.7109375
- 0.02850341796875
can 1.5751953125
cer 0.00067138671875
▁treatment 2.662109375
, 1.3896484375
▁Mar 9.7421875
im 10.4453125
ast 0.034881591796875
at 2.8371810913085938e-05
, 0.294189453125
▁is 1.1318359375
▁expected 0.330322265625
▁to 0.043243408203125
▁be 0.1470947265625
▁presented 0.8642578125
. 0.14404296875
▁Consider 8.46875
ed 0.609375
▁a 1.2578125
▁potential 1.9873046875
▁break 2.646484375
through 0.00791168212890625
▁in 1.001953125
▁cancer 1.248046875
▁th 4.72265625
era 0.0028705596923828125
pe 0.01531219482421875
ut 0.0005970001220703125
ics 0.040863037109375
, 0.09796142578125
▁Mar 0.56005859375
im 0.00959014892578125
ast 0.00366973876953125
at 0.006587982177734375
▁has 1.48046875
▁gar 4.26953125
ner 2.300739288330078e-05
ed 0.00021660327911376953
▁attention 2.568359375
▁for 1.7490234375
▁its 0.068359375
▁unique 2.5234375
▁mechanism 0.7490234375
▁of 0.043914794921875
▁action 0.0266571044921875
▁and 1.4833984375
▁prom 2.361328125
ising 0.0006318092346191406
▁pre 2.693359375
cl 0.64404296875
in 0.0002281665802001953
ical 0.0005698204040527344
▁results 1.359375
. 0.3447265625
<0x0A> 0.66162109375
Develop 5.83984375
ed 0.035400390625
▁by 0.37841796875
▁British 0.71630859375
▁Bi 0.0201416015625
ote 0.0006208419799804688
ch 0.004405975341796875
, 0.38427734375
▁Mar 0.1756591796875
im 0.0019989013671875
ast 0.00025177001953125
at 0.00014710426330566406
▁falls 10.328125
▁under 0.359619140625
▁a 1.6650390625
▁class 0.8779296875
▁of 0.01108551025390625
▁dru 0.63818359375
gs 4.649162292480469e-06
▁known 0.2015380859375
▁as 0.0009717941284179688
▁matrix 1.935546875
▁metal 0.01678466796875
lo 0.00021326541900634766
prote 0.03228759765625
in 0.028839111328125
ase 0.1544189453125
▁in 1.150390625
hib 0.00027871131896972656
itors 0.0029392242431640625
, 1.4658203125
▁which 0.2232666015625
▁work 1.685546875
▁by 0.09808349609375
▁target 1.919921875
ing 0.0006022453308105469
▁specific 1.8974609375
▁en 0.366943359375
zym 3.325939178466797e-05
es 0.0019855499267578125
▁involved 1.076171875
▁in 0.00012958049774169922
▁the 0.96044921875
▁pro 3.84765625
gression 0.10064697265625
▁and 1.5927734375
▁spread 0.327880859375
▁of 0.005680084228515625
▁cancer 0.1290283203125
. 0.76953125
▁Pre 4.7890625
lim 2.9765625
inary 0.00010502338409423828
▁studies 1.150390625
▁have 0.293212890625
▁shown 0.5078125
▁prom 3.8046875
ising 7.128715515136719e-05
▁results 0.1094970703125
, 1.2275390625
▁suggesting 2.818359375
▁that 0.054901123046875
▁Mar 0.1131591796875
im 0.0015802383422851562
ast 7.534027099609375e-05
at 0.00018739700317382812
▁may 0.62109375
▁be 0.7939453125
▁effective 0.5263671875
▁in 0.0836181640625
▁comb 5.44921875
ating 0.0423583984375
▁a 0.473388671875
▁range 0.705078125
▁of 6.389617919921875e-05
▁cancer 1.185546875
▁types 0.01453399658203125
. 2.37109375
▁However 3.4296875
, 0.0005283355712890625
▁further 3.1640625
▁evidence 3.193359375
▁is 0.31396484375
▁required 2.439453125
▁to 0.1405029296875
▁validate 2.314453125
▁these 0.390869140625
▁early 4.3125
▁find 0.038665771484375
ings 1.7881393432617188e-06
▁and 0.5654296875
▁evaluate 5.140625
▁its 1.798828125
▁safety 2.099609375
▁and 0.09130859375
▁effic 0.11395263671875
acy 2.5987625122070312e-05
▁in 0.183349609375
▁clin 1.072265625
ical 0.0002334117889404297
▁settings 1.48046875
. 0.01171875
<0x0A> 0.035247802734375
The 1.4404296875
▁ES 1.0556640625
MO 6.61611557006836e-05
▁meeting 0.406494140625
▁provides 2.408203125
▁an 1.0556640625
▁opport 3.67578125
une 0.003658294677734375
▁platform 0.1724853515625
▁for 0.155029296875
▁research 2.890625
ers 0.00273895263671875
▁and 0.413330078125
▁ph 4.953125
arma 0.0014514923095703125
ce 0.024139404296875
ut 1.5974044799804688e-05
ical 0.00011396408081054688
▁companies 0.050750732421875
▁to 0.068603515625
▁show 1.87109375
case 0.00012123584747314453
▁their 0.1859130859375
▁adv 5.2109375
anc 0.228759765625
ements 3.0159950256347656e-05
▁and 1.41015625
▁eng 3.515625
age 0.00030612945556640625
▁in 0.248291015625
▁discuss 1.8310546875
ions 7.355213165283203e-05
▁surrounding 1.90234375
▁cutting 3.26953125
- 0.001209259033203125
edge 9.369850158691406e-05
▁cancer 1.2685546875
▁ther 1.484375
ap 0.00905609130859375
ies 7.510185241699219e-06
. 0.033203125
▁Anal 3.671875
yst 0.0013256072998046875
s 0.0074005126953125
▁eager 4.21484375
ly 0.006679534912109375
▁anticip 0.802734375
ate 0.005168914794921875
▁the 0.336669921875
▁presentation 0.81396484375
▁on 5.30078125
▁Mar 0.060455322265625
im 0.0021305084228515625
ast 0.00026535987854003906
at 0.0003333091735839844
, 0.34716796875
▁as 1.001953125
▁it 0.177490234375
▁is 2.18359375
▁anticip 4.3359375
ated 0.00022733211517333984
▁to 0.10064697265625
▁provide 0.8984375
▁cru 3.029296875
cial 8.344650268554688e-06
▁ins 0.353759765625
ights 8.106231689453125e-06
▁into 0.1026611328125
▁its 1.9912109375
▁potential 0.25927734375
▁as 1.060546875
▁a 0.04412841796875
▁vi 3.27734375
able 8.225440979003906e-06
▁anti 4.7890625
- 8.52346420288086e-05
can 0.00243377685546875
cer 1.2516975402832031e-05
▁treatment 0.255615234375
. 0.11187744140625
<0x0A> 0.2156982421875
If 5.84765625
▁the 1.3974609375
▁data 1.9951171875
▁presented 0.82470703125
▁at 0.11029052734375
▁the 0.289306640625
▁ES 1.0498046875
MO 0.00014078617095947266
▁meeting 0.0950927734375
▁align 4.1328125
s 0.08734130859375
▁with 0.0174560546875
▁previous 1.6171875
▁studies 1.4482421875
, 0.2061767578125
▁Mar 0.9619140625
im 0.0017805099487304688
ast 0.0001571178436279297
at 0.0004341602325439453
▁could 0.73974609375
▁potentially 2.61328125
▁revolution 0.9541015625
ize 0.01456451416015625
▁the 0.5439453125
▁field 1.5283203125
▁of 0.0021305084228515625
▁on 1.4013671875
col 0.002964019775390625
ogy 9.775161743164062e-06
, 1.216796875
▁offering 0.330322265625
▁new 2.361328125
▁hope 0.31103515625
▁for 0.89501953125
▁patients 0.7568359375
▁batt 2.08984375
ling 0.00017189979553222656
▁various 2.064453125
▁forms 0.9228515625
▁of 0.00015914440155029297
▁cancer 0.0711669921875
. 0.01541900634765625
▁However 2.0234375
, 6.949901580810547e-05
▁it 1.1484375
▁is 0.26416015625
▁worth 3.40234375
▁not 0.0462646484375
ing 1.4424324035644531e-05
▁that 0.0016145706176757812
▁the 1.1123046875
▁drug 1.533203125
▁is 0.548828125
▁still 0.148681640625
▁in 0.1309814453125
▁the 0.62353515625
▁early 0.23193359375
▁stages 0.0161590576171875
▁of 0.0007958412170410156
▁development 0.779296875
, 1.1103515625
▁and 0.023284912109375
▁further 0.91845703125
▁clin 0.447509765625
ical 2.300739288330078e-05
▁tri 0.044189453125
als 3.5762786865234375e-07
▁and 1.15625
▁regul 0.4150390625
atory 5.841255187988281e-06
▁appro 0.00894927978515625
val 3.5762786865234375e-06
s 0.152587890625
▁will 1.205078125
▁be 0.028900146484375
▁necessary 1.001953125
▁before 0.088134765625
▁it 0.0258026123046875
▁can 0.08099365234375
▁be 0.113037109375
▁made 1.0546875
▁widely 1.2578125
▁available 0.016571044921875
▁to 0.7646484375
▁patients 0.137451171875
. 0.0178985595703125
<0x0A> 0.23779296875
As 2.5859375
▁the 0.64599609375
▁ES 1.0576171875
MO 8.130073547363281e-05
▁meeting 0.05816650390625
▁approaches 0.401611328125
, 0.01486968994140625
▁anticip 3.541015625
ation 0.0009522438049316406
▁is 0.8818359375
▁pal 3.697265625
p 0.00030350685119628906
able 0.0002486705780029297
▁among 0.71826171875
▁anal 1.830078125
yst 2.6226043701171875e-05
s 0.0008006095886230469
▁who 4.89453125
▁are 0.71875
▁closely 2.78125
▁monitoring 0.54736328125
▁develop 2.25390625
ments 1.2516975402832031e-05
▁in 1.2158203125
▁cancer 2.263671875
▁research 1.5185546875
. 0.402099609375
▁The 1.3017578125
▁presentation 0.8427734375
▁on 0.767578125
▁Mar 0.00861358642578125
im 0.001617431640625
ast 3.159046173095703e-05
at 5.6743621826171875e-05
▁holds 4.03125
▁the 1.677734375
▁promise 3.775390625
▁of 0.024627685546875
▁providing 1.0185546875
▁additional 5.6328125
▁evidence 1.6630859375
▁and 3.076171875
▁further 3.515625
ing 1.42578125
▁our 0.5654296875
▁understanding 0.0201568603515625
▁of 0.0005211830139160156
▁this 0.353515625
▁innov 1.9892578125
ative 5.7816505432128906e-05
▁treatment 1.078125
' 3.876953125
s 0.00023233890533447266
▁potential 0.037322998046875
▁to 1.13671875
▁combat 2.49609375
▁cancer 0.213134765625
, 3.578125
▁insp 5.8046875
iring 0.002437591552734375
▁hope 0.419189453125
▁for 0.67724609375
▁a 1.8291015625
▁future 1.748046875
▁where 0.494384765625
▁more 2.453125
▁effective 0.340087890625
▁ther 2.232421875
ap 0.0002887248992919922
ies 1.9431114196777344e-05
▁may 5.39453125
▁be 0.322998046875
▁available 0.35595703125
▁to 0.453857421875
▁those 1.1083984375
▁in 1.0703125
▁need 0.004947662353515625
. 0.01029205322265625
